Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Assets (2020 - 2025)

Arcutis Biotherapeutics has reported Assets over the past 6 years, most recently at $433.0 million for Q4 2025.

  • Quarterly results put Assets at $433.0 million for Q4 2025, up 24.1% from a year ago — trailing twelve months through Dec 2025 was $433.0 million (up 24.1% YoY), and the annual figure for FY2025 was $433.0 million, up 24.1%.
  • Assets for Q4 2025 was $433.0 million at Arcutis Biotherapeutics, up from $371.0 million in the prior quarter.
  • Over the last five years, Assets for ARQT hit a ceiling of $508.9 million in Q3 2022 and a floor of $293.0 million in Q3 2023.
  • Median Assets over the past 5 years was $383.2 million (2021), compared with a mean of $393.3 million.
  • Biggest five-year swings in Assets: surged 95.45% in 2021 and later crashed 42.43% in 2023.
  • Arcutis Biotherapeutics' Assets stood at $408.2 million in 2021, then rose by 10.08% to $449.3 million in 2022, then dropped by 24.02% to $341.4 million in 2023, then increased by 2.2% to $348.9 million in 2024, then rose by 24.1% to $433.0 million in 2025.
  • The last three reported values for Assets were $433.0 million (Q4 2025), $371.0 million (Q3 2025), and $352.4 million (Q2 2025) per Business Quant data.